Women in perimenopause and within 5 years after menopause. Inclusion criteria are those with an increased oxidative stress marker: more than 300 Carr Units measured by the Diacron-reactive oxygen metabolites test and low antioxidant state, less than 2000 micro Units, by the biological anti-oxidant potential test.
Conditions
Interventions
Participants are taken one capsule (an astaxanthin capsule including 12mg of astaxanthin) once a day for 12 weeks.
A placebo capsule is taken one capsule once a day for 12 weeks.
Sponsors
JT Chen Clinic
Eligibility
Sex/Gender
Female
Inclusion criteria
Inclusion criteria: Women in perimenopause or within 5 years after menopause. Inclusion criteria are those with an increased oxidative stress marker: more than 300 Carr Units measured by the Diacron-reactive oxygen metabolites test and low antioxidant state, less than 2000 micro Units, by the biological anti-oxidant potential test.
Exclusion criteria
Exclusion criteria: A: women with under 300 Carr Units measured by the Diacron-reactive oxygen metabolites test and a normal antioxidant state, over 2000 micro Units, by the biological anti-oxidant potential test. B: smoker. C: women receiving hormone replacement therapy. D: women taking antioxidant supplements or vitamins. E: women receiving treatment for chronic heart failure, renal failure, hepatitis, or malignancies. F: The doctor approved inappropriate incorporating for this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Before, and 4, 8, 12 weeks after the supplement, all participants are interviewed for their medical histories, subjective symptoms, anti-aging common questionnaire, simplified menopausal index, questionnaire for poor circulation, and the status of the supplement. Measurements of body height and weight, blood pressure, and blood oxidative stress measured by the Diacron-reactive oxygen metabolites test and antioxidant state by the biological anti-oxidant potential test. | — |
Secondary
| Measure | Time frame |
|---|---|
| General blood count, coagulation and fibrinolysis, liver and kidney function, lipids and lipoproteins, inflammatory and oxidative markers, 17-beta E2, FSH, and general urinalysis were measured before and 12 months after the treatment. | — |
Countries
Japan
Contacts
Public ContactJui-Tung Chen
JT Chen Clinic Gynecology
Outcome results
None listed